 Home > Active Ingredient News > Antitumor Therapy > Blood: Carfilzomib, lenalidomide and dexamethasone combined with bone marrow transplantation can effectively treat multiple myeloma!

Blood: Carfilzomib, lenalidomide and dexamethasone combined with bone marrow transplantation can effectively treat multiple myeloma!

 Last Update: 2021-08-03
 Source: Internet
 Author: User

Tags

fast clotting blood

treatment

benefits coq10 heart

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bortezomib, lenalidomide, and dexamethasone combined with stem cell transplantation are the standard treatments for eligible patients with multiple myeloma
.

Because remission can deepen over time, longer and more effective induction/consolidation phases are needed

stem cell

This is a phase 2 clinical trial that recruits patients with multiple myeloma who can be transplanted to receive carfilzomib (K) 20/36 mg/m2 (days 1-2/8-9/15-16) , Lenalidomide (R) 25 mg (day 1-21) and dexamethasone (d) 20 mg (day 1-2/8-9/15-16/22-23) treatment, 28 days Course of treatment
.

All patients underwent bone marrow transplantation after 4 courses and received lenalidomide (10 mg, day 1-21) for maintenance treatment for one year

Can assess the patient's remission

Overall, 48 patients were screened and 46 of them were recruited into the group; 21% of patients had poor cytogenetics
.

Among the 42 patients who could be evaluated after consolidation therapy, 26 achieved complete remission under strict conditions (CR 61.

Screening Among 42 patients who could be evaluated after consolidation treatment, 26 achieved complete remission under strict conditions (CR 61.

Progression-free survival rate of patients with different MRD status

The median time to obtain CR was 10.
6 months
.

According to multi-parameter flow cytometry and next-generation sequencing technology, 69.

At a median follow-up of 60.

Heart blood vessels of heart failure thrombosis infection

All in all, 8 courses of KRd treatment can achieve rapid and profound remission in newly diagnosed multiple myeloma patients who are eligible for transplantation , and the safety is acceptable, but cardiovascular adverse events need to be closely monitored

8 courses of KRd treatment can obtain rapid and profound remission for newly diagnosed multiple myeloma patients who are eligible for transplantation , and the safety is acceptable, but it is necessary to closely monitor cardiovascular adverse events.

Original source:

Murielle Roussel, et al.

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.